POP-UP: a Single-arm, Two-cohort Study: an 8-week Trimodal Pre-habilitation Program for Patients With Pancreatic Ductal Adenocarcinoma and Oesogastric

Other illness

• Evidence of metastatic disease at imaging (validated in multidisciplinary team evaluation),
• Any medical (including cardiovascular, respiratory, psychiatric, musculoskeletal, or neurological) condition contra-indicating exercise practice,
• Patients with medical contraindication to surgery due to general condition or comorbidities

Other

• Histology of other than adenocarcinoma,
• Pregnancy or breast-feeding,
• Patient under a legal protection regime (guardianship, curatorship, judicial safeguard) or administrative decision or incapable of giving his/her consent,

• Signed and dated patient informed consent form (ICF) and willingness to comply with all study procedures and availability for the study duration,
• Histologically or cytologically proven, localized PDAC or OGC,
• Indication to a neoadjuvant treatment with triplet chemotherapy for ≥ 4 cycles (8 weeks) validated by the multidisciplinary board, Note: Patient treated for PDAC, dose reduction of oxaliplatin or irinotecan is authorized.
• Age \> 18 years; If aged ≥ 75 years: G8 score must be ≥ 14 and if \< 14 validation of oncogeriatric specialist,
• Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1 at the inclusion visit,
• No prior treatment for PDAC or OGC before starting chemotherapy (FLOT or FOLFIRINOX),
• At least one measurable or evaluable lesion as assessed by Computerized Tomography scan or Magnetic resonance imaging according to RECIST 1.1 and feasibility of repeated radiological assessments,
• Adequate hematologic and end-organ function allowing the triple combination chemotherapy protocol,
• Registration in a national health care system (PUMa - Protection Universelle Maladie included).